The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Lord, excellent questions and absolutely they deserve an answer. Otherwise I shall suggest Tom Winnifrith puts Opti on his danger list rather than his tips list...
I've submitted a couple of fairly hard-hitting questions, so it'll be interesting to see if either is answered.
One relates to when Opti will actually make an operating profit (ignoring gains from share spin offs) & why a dilutive placing was chosen over further sales of spin off shares in March 2024 (presumably because SBTX & PBTX were both trading so low at the time!)
My other question is about SOH's infamous projected customer turnover bands (remember his forecasts several years ago?). I believe he grouped our then customer base into bands. From memory, these ranged from projected annual sales of £100K + each, up to a band with forecast annual sales of £500K + per customer. My question is why - 5 or more years on - group turnover has fallen way short of the value these projections suggested & whether the latest figures will show enough has been done to address this.
I look forward to this. I generally can't attend due to work but appreciate the feedback on here from posters. Will also catch the YouTube after.
Https://www.londonstockexchange.com/news-article/OPTI/investor-update/16463447
mol
Remember them?
well perhaps a bit of good news - albeit the travel budget perhaps took a hit if photos are contemporaneous
https://www.linkedin.com/posts/rohit-noronha-5888b115_weightmanagement-nutraceuticals-functionalfoods-activity-7185556319360225281-G1Qt?trk=public_profile
mol
Well the reviews aren't nor am i impressed at all with our online sales presence - amateurish - as noted before
still waiting on boots
of which the online launch of our own products was scheduled for qtr 1 2024 by agreement and nowt to do with boots instore category rebuild
22 September 2023
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that it has reached agreement to launch its own brands of SlimBiome®, GoFigure®, and Snacksmart® products online with Boots in Q1 2024 with a potential store launch in May 2024, subject to Boots instore category rebuild.
tick tock re this pronouncement Stephen - the rns categorically states agreement reached for launch in Qtr 1 2024
mol
Per's wife Laura still notes herself as a senior consultant to us on her linkedin profile
Consultant
Rehne consulting
Feb 2019 - Present 5 years 4 months
bishops stortford
OPTIBIOTIX HEALTH PLC
Senior Consultant
OPTIBIOTIX HEALTH PLC
Jan 2018 - Present 6 years 5 months
https://find-and-update.company-information.service.gov.uk/company/11704034
mol
The online sales must be going well
I note Shiraz Butt appointed a Director on 01 January 2024
mol
Oops meant to also post
https://www.probi.com/annual-report/en/
mol
Stephen has mentioned Probi a number of times over the years so I thought I would just do a bit of doodling
and their relationship with clasado biosciences seems to be going from strength to strength
https://www.probi.com/search/?query=clasado
I recognise at least three of the team at Clasado
https://clasado.com/corporate/
just a bit of info
mol
Can't see anything wrong with having different types of soups.
It still feels like tinkering at the edges. Small scale.
Still waiting for a sweetbiotix RNS for commercialisation.
We now have the undernoted
https://optibiotix.com/wp-content/uploads/2024/04/Slimbiome-Soup.pdf
in addition to
https://optibiotix.online/products/snacksmart-soups
nothing like different marketing messages ............
who is responsible for this i wonder?
perhaps i'm being a bit harsh as one is under snacksmart and the other isn't
nah - lol
mol
It would be very helpful to have a similar presentation this year - especially as Graham now in position - prior to year end audited results generally late May/June
https://www.walbrookpr.com/docs/librariesprovider48/default-document-library/investors/optibiotix---investor-presentation-may-2023.pdf
mol
Sbtx a very useful addition afterwards as it basically became a vehicle to raise funds to continue the main thrust which i don't think even Stephen had anticipated nor intended at outset of its separate existence
mol
Oh come on martinu we've only had 10 years to date from listing (12 in total)
OptiBiotix has established a pipeline of microbiome modulators that impact on energy harvest, appetite
suppression, and lipid and cholesterol management. The development pipeline is fuelled by its proprietary
platform technologies including:
OptiScreen ® : A proprietary high throughput screening and optimisation technology platform designed to
identify microbes within the human microbiome with metabolic pathways which can interact with human
physiological processes and bring health benefits.
OptiBiotic ® : A proprietary platform technology which generates novel compounds and screens them for
their ability to modulate the human microbiome and its microbial end products. This creates the potential to
influence host metabolism and physiology for the prevention and management of disease.
These platforms have been validated in development programmes which have established a pipeline of
compounds which modulate the human microbiome to bring health benefits, including:
● 3 microbial strains which have demonstrated the ability to reduce cholesterol by 71 per cent.,
78 per cent., and 82 per cent., respectively, in laboratory studies;
● An ingredient formulation scientifically formulated by its international key opinion leaders to support
and sustain weight loss in overweight and obese patients. The formulation has been developed so
that components act differently in both their mechanism and site of action; and
● A compound which can selectively enhance the growth of specific microbial species in the human
microbiome. Selectively enhancing specific microbial species creates the capability to modify the human
microbiome specific to health needs.
In summary, the research programme to be followed by OptiBiotix is expected to include:
Cholesterol and lipid management product
The three strains shown to reduce cholesterol in the laboratory will be tested to confirm the absence of
antimicrobial resistance and virulence factors, and to assess gut survivability and manufacturing scale up
capability. On completion of these studies the product will be tested in a human nutritional study to assess
the ability of the product to reduce human cholesterol in at risk populations. Following analysis of the data,
the results will be published in clinical journals.
Microbiome modulator generation and screening
High throughput screening of numerous microbial strains will be used to identify strains with the enzymic
capability of producing novel sugars. Microbial strains with high enzymic activity will be selected and reaction
conditions created to produce sufficient novel sugars for an assessment of their commercial potential,
including:
● identification of novel non-digestible sugars with a sweet taste, low calorific value, and an insulin
independent metabolism with commercial potential as sugar substitutes;
lpldl slimbiome and sweetbiotix
sbtx a
Shame the Opti message doesn't reach a wider audience to promote healthy, sustainable weight loss, with reduced risk. Maybe one day...
A recent article written by Stephen
https://nmc-magazine.com/is-there-a-more-sustainable-approach-to-weight-loss-than-injectable-drugs/
i'm back to doing a bit of doodling
bw all
mol
Fair points around. A necessary step. But someone once said, "nothing takes forever". With SOH/Opti I'm not so sure! And for all his failings I quite like Uncle Stephen.
Malco, if you bothered to read the Morepen related RNS you would realise this is the manufacturing agreement for the products that Dr Morepen will market and distribute financial details and timelines are ""We are pleased to announce this agreement with Morepen, a well-known and trusted supplier to pharmacies, physicians, and retail customers across India. Morepen brings an extensive sales team with experience of highly differentiated scientific products and countrywide access to a network of around 500,000 pharmacies across India. Based on current forecasts, the Directors anticipate this agreement could contribute in the region of £6-7 million revenue per annum in the next four to five years.""
Yet another deal announced but with zero financial info given and no timelines to market.
SOH is very good at producing RNS with virtually no information. Probably another deal which will not produce any meaningful revenue in the near future.
Let's see revenues from it. I've lost count of the amount of deals Opti have signed over the years, deals which generated a lot more in the way of excitement than money.
I don't like to be cynical but large paper losses and a long time invested will do that to a man.
This deal looks impressive on the surface.
Question is how much revenue from sales this will provide for Opti from royalties etc.
On the basis of 2022 FY, it will be quite a while just to break even. Based just on SlimBiome etc. Roughly 50% gross profit. And £2.75m admin costs. This ignores 20% reduction in (some?) salaries. And any accounting for stake in SBTX, PBX. And the ever elusive SweetBiotix.
SOH has talked about £7m revenue in Y5 from India deal, in RNS from Feb. And some large % increases to sales online (from low bases?). And some apparently good orders in tonnages. But I don't see FY 23 being anything other than £1m plus operating loss.
We live in hope of Sweets.